TIDMMXCT TIDMTTM
RNS Number : 9374N
MaxCyte, Inc.
04 February 2021
MaxCyte, Inc.
("MaxCyte" or the "Company")
Director Dealings and Issue of Equity
Gaithersburg, Maryland - 4 February 2021: MaxCyte (LSE: MXCT,
MXCL), the global cell-based medicines and life sciences company,
announces that further to the announcement of a GBP40 million
(approx. $55 million) Subscription via a private placement of
5,740,000 new shares of common stock (the "Subscription
Announcement") on 3 February, 2021, Doug Doerfler, Chief Executive
Officer and a Founder of the Company, Ron Holtz, Senior Vice
President and Chief Accounting Officer and J. Stark Thompson,
Non-Executive Chairman, have exercised options in the amount of
755,000 shares of common stock, $0.01 par, of the Company ("Common
Stock") ("Exercise") in aggregate. The 755,000 new shares of Common
Stock issued pursuant to the Exercise ("New Options Common Stock")
have been sold by Doug Doerfler, Ron Holtz and J. Stark Thompson at
a price of 700 pence per Common Stock ("Sale").
Following the Exercise and Sale, Mr Doerfler's holding of Common
Stock remains unchanged at a total of 433,197 shares and Mr Holtz's
holding of Common Stock remains unchanged at a total of 150,251
shares, representing 0.5% and 0.2%, respectively, of the enlarged
issued share capital of the Company following the Subscription and
the Exercise. Mr. Doerfler, Mr. Holtz and Dr Thompson hold a
further 2,313,480, 1,014,892 and 211,333 options over Common Stock
respectively.
Total voting rights
Application has been made for admission of the 755,000 New
Options Common Stock to trading on AIM, which is anticipated to
occur at 8:00am on 8 February 2021 ("Options Stock Admission"). The
New Options Common Stock will rank pari passu with the existing
shares of common stock of the Company and will trade in the
unrestricted line of Common Stock trading under the symbol MXCT.
The total issued stock capital of the Company following the Options
Stock Admission and the admission to trading on AIM of the
5,740,000 shares of Subscription Common Stock ("Subscription Stock
Admission") will be 83,917,169 shares of common stock. Following
Option Stock Admission and Subscription Stock Admission,
Shareholders in the Company may use this figure as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, the stock capital of the Company.
Following Subscription Stock Admission (which comprises First
Admission and Second Admission) and Options Stock Admission, the
number of unrestricted shares of Common Stock trading under the
symbol 'MXCT' will be 73,687,080; the number of restricted shares
of Common Stock trading under the symbol 'MXCL' will be 9,900,089
and the number of restricted shares of Common Stock trading under
the symbol 'MXCN' will be 330,000.
Save as otherwise defined, capitalised terms used in this
announcement have the meanings given to them in the Subscription
Announcement.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 ("MAR").
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Doug Doerfler
=============================== ============================================
2 Reason for the notification
=============================================================================
a) Position/status Chief Executive Officer
=============================== ============================================
b) Initial notification/Amendment Initial notification
=============================== ============================================
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=============================================================================
a) Name MaxCyte, Inc.
=============================== ============================================
b) LEI 54930053YHXULRFCU991
=============================== ============================================
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
=============================================================================
a) Description of Common Stock of $0.01 each
the financial
instrument, type
of instrument
=============================== ============================================
b) Identification US57777K1060
Code
=============================== ============================================
c) Nature of the Exercise of options and Sale of Common
transaction Stock by PDMR
=============================== ============================================
d) Price(s) and volume(s) Price(s) Volume(s)
=============================== ================ ==========================
N/A 500,000 (option exercise)
700 pence 500,000 (sale of common
stock)
=============================== ================ ==========================
e) Aggregated information N/A
- Aggregated volume N/A
- Price N/A
=============================== ============================================
f) Date of the transaction 3 February 2021
=============================== ============================================
g) Place of the transaction London Stock Exchange, AIM Market (XLON)
=============================== ============================================
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Ron Holtz
=============================== =============================================
2 Reason for the notification
==============================================================================
a) Position/status Senior Vice President and Chief Accounting
Officer
=============================== =============================================
b) Initial notification/Amendment Initial notification
=============================== =============================================
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==============================================================================
a) Name MaxCyte, Inc.
=============================== =============================================
b) LEI 54930053YHXULRFCU991
=============================== =============================================
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
==============================================================================
a) Description of Common Stock of $0.01 each
the financial instrument,
type of instrument
=============================== =============================================
b) Identification US57777K1060
Code
=============================== =============================================
c) Nature of the transaction Exercise of options and Sale of Common
Stock by PDMR
=============================== =============================================
d) Price(s) and volume(s) Price(s) Volume(s)
=============================== ================= ==========================
N/A 225,000 (option exercise)
700 pence 225,000 (sale of common
stock)
=============================== ================= ==========================
e) Aggregated information N/A
- Aggregated volume N/A
- Price N/A
=============================== =============================================
f) Date of the transaction 3 February 2021
=============================== =============================================
g) Place of the transaction London Stock Exchange, AIM Market (XLON)
=============================== =============================================
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name J. Stark Thompson
=============================== ===========================================
2 Reason for the notification
============================================================================
a) Position/status Non-Executive Chairman and PDMR
=============================== ===========================================
b) Initial notification/Amendment Initial notification
=============================== ===========================================
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
============================================================================
a) Name MaxCyte, Inc.
=============================== ===========================================
b) LEI 54930053YHXULRFCU991
=============================== ===========================================
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
============================================================================
a) Description of Common Stock of $0.01 each
the financial instrument,
type of instrument
=============================== ===========================================
b) Identification US57777K1060
Code
=============================== ===========================================
c) Nature of the transaction Exercise of options and Sale of Common
Stock by PDMR
=============================== ===========================================
d) Price(s) and volume(s) Price(s) Volume(s)
=============================== ================ =========================
N/A 30,000 (option exercise)
700 pence 30,000 (sale of common
stock)
=============================== ================ =========================
e) Aggregated information N/A
- Aggregated volume N/A
- Price N/A
=============================== ===========================================
f) Date of the transaction 3 February 2021
=============================== ===========================================
g) Place of the transaction London Stock Exchange, AIM Market (XLON)
=============================== ===========================================
For the purposes of MAR, the person responsible for arranging
for the release of this Announcement on behalf of the Company is
Maher Masoud, General Counsel.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Accounting Officer +1 301 944 1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Joint Corporate Broker
Stifel Nicolaus Europe Limited
Healthcare Investment Banking
Nicholas Moore / Ben Maddison /
Samira Essebiyea
Corporate Broking
Nick Adams +44 (0) 20 7710 7600
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
About MaxCyte
MaxCyte is a world-leading provider of cell-engineering enabling
technology and is responsible for helping to bring next-generation
cell and gene-editing therapies to life. The Company's technology
is deployed by leading drug developers worldwide, including all of
the top ten global biopharmaceutical companies. MaxCyte licences
have been granted for more than 140 cell therapy programmes, with
more than 100 licensed for clinical use, and the Company has now
entered into twelve clinical/commercial license partnerships with
leading cell therapy and gene editing developers. MaxCyte was
founded in 1998, is listed on the London Stock Exchange (LSE: MXCT,
MXCL) and is headquartered in Gaithersburg, Maryland, US. For more
information, visit www.maxcyte.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHTJMBTMTJMTPB
(END) Dow Jones Newswires
February 04, 2021 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024
